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The perceived usefulness of registries is that they are
a pragmatic and representative tool to assess the im-
pact of new treatments as they are introduced into
practice. They give information on outcomes, learning
curves and dissemination of the new technique,
though the validity of the results is often viewed
with suspicion because they are voluntary and obser-
vational. The results from a number of randomised
controlled trials (RCTs) of Endovascular Aneurysm
Repair (EVAR) are now available to compare with
the outcomes contained within registries; such a
comparison has been carried out by Leurs et al.1
Leurs identified patients in the EUROSTAR cohort
with risk factors similar to those in the Dutch
Randomised Endovascular Aneurysm Management
(DREAM) trial. A group of 856 EUROSTAR patients
were selected based on ASA distribution and matched
to those in the DREAM trail. Outcomes from the reg-
istry and RCT are strikingly similar, supporting the
case that the registry data is a valid representation
of EVAR outcomes and the DREAM trial results are
generalisable. Should we be surprised at this, prob-
ably not. The weaknesses of observational methods
may have been overemphasised, with a number of re-
ports now showing that as long as the methodological
weaknesses are recognised and limited, either by
design or analysis, observational study outcomes are
as valid as more explanatory RCTs.2e4
Leurs et al’s findings strengthen the case for theuseof
registries to assess new techniques, and that in the case
ofEVARtheuseof registrieswasworthwhile.This is im-
portant as device technology continues to develop rap-
idly and long-termdevice related complications remain
problematic. Further large randomised trials for EVAR
in AAA are unlikely, at least in the near future, yet the
registries remain as important ongoing tools. The prob-
lem with the EVAR registries is the lack of collection of
data for the comparator treatment conventional open
repair, and so it is not possible to perform a true cohort
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ing larger or linked databases. In the UK, the National
Vascular Database collects data for both open repair
and EVAR, and with appropriate information technol-
ogy andweb-based systems, it should be possible to en-
sure registry data for the UK registry of Endovascular
Treatment of Aneurysms (RETA) is collected and com-
parator data for open repair obtained to allow compar-
isons in the future. Similar databases could be extended
across Europe and provide a model for assessment of
new techniques. Such well designed and maintained
registries could produce evidence negating the need
for some trials, saving time and expense, particularly
if areas of uncertainty are exploredusing othermethods
such as computer modeling.
To enable this to occur requires a sound financial
base to provide the appropriate infrastructure to
establish, maintain and analyse registries. In the UK
the National Institute for Health and Clinical Excel-
lence recommend that EVAR cases are submitted to
an existing registry,5 yet this organization has no formal
arrangements to help maintain registries. The recent
announcement of the closure of the EUROSTAR regis-
try shows that without adequate financial support,
such valuable resources, and their ability to inform
practice, are easily lost.
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Multi-level methodology in our study, was able
to rank the 24 ICUs from the development study
(Hadjianastassiou VG. Br J Surg 2005) and the
2 ICUs used in the current study (the data from the
smaller unit were collected prospectively and could
not simply be discarded), according to the level of ad-
justment that needed to take place for each hospital,
and it certainly did not hide differences. On the con-
trary, contemporary models in vascular surgery only
take into account the patient case-mix and ignore
this ‘‘hospital effect’’. We agree with Tang et al that
models should only be used for the purpose they
were designed for which is why we provided the ev-
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We advocate the idea that patient outcome is not only
a function of the patient case-mix but instead predic-
tive models should also adjust for the individual
hospital-related factors (structure and process of
care). This methodology is essential when there is
‘‘clustering’’ of patients (i.e. patients’ results from
the same hospital are more likely to be correlated)
such as in a national setting. Multilevel models have
already been used extensively in comparison studies
focusing: on the Bristol enquiry (Aylin P. Lancet
2001); in colorectal cancer survival (Kee F. BMJ 1999,
Tekkis PP. BMJ 2003); in gastro-oesophageal surgery
(McCulloch P. BMJ 2003).
idence to warn investigators not to use POSSUM/
VBHOM models in the post-operative AAA setting.
A predictive model attempts to summate into a
single value (‘‘predicted risk’’) the ‘‘case-mix’’ or the
patient-related variables which have a clinical influ-
ence on outcome. Physiological data temporally closer
(post-operative data) to this outcome more accurately
reflect the state of the patient than data before a thera-
peutic intervention. Otherwise, prediction modelling
would be more akin to ‘‘guessing’’ future events.
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